4-Hydroxy-5,6-Dihydro-2H-pyran-2-ones. 3. Bicyclic and hetero-aromatic ring systems as 3-position scaffolds to bind to S1′ and S2′ of the HIV-1 protease enzyme
Edmund L. Ellsworth(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Neil M.H. Graham(UK Dementia Research Institute), Donna Ferguson(Pfizer (United States)), Caroline Nouhan(Gaertner (United States)), Greg Zeikus(Pfizer (United States)), Donald Hupe(Pfizer (United States)), J. V. N. Vara Prasad(Pfizer (United States)), Tod P. Holler(Pfizer (United States)), John M. Domagala(Pfizer (United States)), Susan E. Hagen(Pfizer (United States))
Cited by 11
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k